Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Back

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Not Recruiting

Open to: FEMALE

Age: 18.0 - N/A

Glasgow Sutton Cambridge Exeter London Manchester

Medical Conditions

Uterine Cervical Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent).

Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2021 Jul 2023

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : 2.0 mg/kg every 3 weeks (Q3W)

Intervention Arm Group : Tisotumab vedotin;

Intervention Type : DRUG
Intervention Description : 1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days

Intervention Arm Group : Chemotherapy;

Intervention Type : DRUG
Intervention Description : 30 mg/m2 IV on Days 1 and 8, every 21 days

Intervention Arm Group : Chemotherapy;

Intervention Type : DRUG
Intervention Description : 1000 mg/m2 IV on Days 1 and 8, every 21 days

Intervention Arm Group : Chemotherapy;

Intervention Type : DRUG
Intervention Description : 100 or 125 mg/m2 IV weekly for 28 days, every 42 days

Intervention Arm Group : Chemotherapy;

Intervention Type : DRUG
Intervention Description : 500 mg/m2 IV on Day 1, every 21 days

Intervention Arm Group : Chemotherapy;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Beatson West of Scotland Cancer Centre
    Glasgow
    G12 0YN
  • The Royal Marsden Hospital (Surrey)
    Sutton
    Other
    SM2 5PT
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge
    Other
    CB2 0QQ
  • Royal Devon and Exeter NHS Foundation Trust
    Exeter
    Other
    EX2 5DW
  • The Royal Marsden Hospital
    London
    Other
    SW3 6JJ
  • The Christie NHS Foundation Trust
    Manchester
    Other
    M20 4BX


The study is sponsored by Seagen Inc. and is in collaboration with Genmab.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04697628
Last updated 16 July 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top